Literature DB >> 8074604

Intravenous immunoglobulin-induced osmotic nephrosis.

N Ahsan1, B F Palmer, D Wheeler, R G Greenlee, R D Toto.   

Abstract

Intravenous immunoglobulin preparations are being used for an increasing number of indications in clinical medicine. To minimize adverse reactions, sugar additives such as sucrose are added to some preparations to serve as stabilizing agents. We describe a patient treated with an immunoglobulin preparation containing sucrose who developed a fully reversible form of acute renal failure with histologic changes characterized by vacuolization and swelling of renal proximal tubular cells. We believe the high concentration of sucrose in the immunoglobulin preparation resulted in osmotic injury to the renal tubules. Such changes, which are identical to those described in humans and experimental animals given intravenous infusions of hypertonic sucrose, have come to be known as osmotic nephrosis. Risk factors for the development of this lesion are renal insufficiency and volume depletion. The risk for such injury can be minimized by further diluting the immunoglobulin preparation and slowing the infusion rate.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8074604     DOI: 10.1001/archinte.154.17.1985

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  12 in total

Review 1.  [Intravenous immunoglobulins in chronic idiopathic myositis].

Authors:  H Michels; G-R Burmester; F Buttgereit
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

Review 2.  Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Authors:  Jan D Lünemann; Falk Nimmerjahn; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-06       Impact factor: 42.937

3.  American Society of Nephrology Quiz and Questionnaire 2013: electrolyte and acid-base.

Authors:  Biff F Palmer; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 8.237

Review 4.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

5.  Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report.

Authors:  Gautam Phadke; Amit Kaushal; Dean R Tolan; Kai Hahn; Thomas Jensen; Petter Bjornstad; Carlos Roncal-Jimenez; Ana Andres Hernando; Miguel A Lanaspa; Mariam Priya Alexander; Aleksandra Kukla; Richard J Johnson
Journal:  Am J Kidney Dis       Date:  2020-05-05       Impact factor: 8.860

Review 6.  Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM.

Authors:  Michael Joannidis; Wilfred Druml; Lui G Forni; A B Johan Groeneveld; Patrick Honore; Heleen M Oudemans-van Straaten; Claudio Ronco; Marie R C Schetz; Arend Jan Woittiez
Journal:  Intensive Care Med       Date:  2010-03       Impact factor: 17.440

7.  True hyponatremia secondary to intravenous immunoglobulin.

Authors:  Minhtri K Nguyen; Anjay Rastogi; Ira Kurtz
Journal:  Clin Exp Nephrol       Date:  2006-06       Impact factor: 2.617

8.  Permanent renal failure induced by pentastarch.

Authors:  Rahima Jamal; Marc Ghannoum; Jean-Francois Naud; Pierre-Paul Turgeon; Martine Leblanc
Journal:  NDT Plus       Date:  2008-06-23

9.  Differential effects of commercial-grade and purified poloxamer 188 on renal function.

Authors:  Martin Emanuele; Balu Balasubramaniam
Journal:  Drugs R D       Date:  2014-06

Review 10.  Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017 : Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine.

Authors:  M Joannidis; W Druml; L G Forni; A B J Groeneveld; P M Honore; E Hoste; M Ostermann; H M Oudemans-van Straaten; M Schetz
Journal:  Intensive Care Med       Date:  2017-06-02       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.